Jury Awards Over $4.8 Million to 10x Genomics in Patent Infringement Case Against Qiagen Subsidiary
A Delaware federal court jury ruled that Parse Biosciences, a subsidiary of Qiagen (QGEN), infringed on three patents held by Scale Biosciences, which is owned by 10x Genomics (TXG). As a result, the jury awarded more than $4.8 million in damages to 10x Genomics. The case centered around intellectual property related to single-cell sequencing technology. The ruling highlights ongoing tensions and legal battles within the biotechnology sector over patent ownership and innovation rights. This outcome could influence future litigation strategies among firms competing for technological leadership in genomic research.
Topics: biotech legal action patents